However, Kusaka et al. have shown that another SGLT2 inhibitor Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy as well as ameliorated cardiac hypertrophy and fibrosis, in association with the attenuation of cardiac oxidative stress and inflammation in prediabetic rats with MetS without significant changes in blood pressure, heart rate or sympathetic activity [34]. This evidence concerns the gene SLC5A2 and metabolic syndrome.